Shares of Nuformix plc (LON:NFX – Get Free Report) were down 12.5% during mid-day trading on Wednesday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.06 ($0.00). Approximately 19,272,414 shares were traded during mid-day trading, an increase of 383% from the average daily volume of 3,989,162 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Down 12.5 %
The firm has a market capitalization of £458,813.60, a PE ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The company has a 50-day moving average price of GBX 0.16 and a 200 day moving average price of GBX 0.18.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- Overbought Stocks Explained: Should You Trade Them?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Small Caps With Big Return Potential
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Investing In Preferred Stock vs. Common Stock
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
